Homocysteine-lowering therapy for preventing atherothrombotic events: its role in high risk population.
Despite clear association between increased level of homocysteine and increased risk for atherothrombotic events, there is currently not enough evidence to initiate homocysteine-lowering vitamins in high risk population in order to improve cardiovascular outcomes in the light of recent clinical trials. Further large-scale adequately powered clinical trials are awaited to clarify this issue.
Acikel
Sadik
S
Dogan
Mehmet
M
Akdemir
Ramazan
R